2022–2025 (latest 4 aligned FYs; v3 window cap 5): revenue $437146 to $3.1M, increasing; diluted EPS -0.03 to -2.00, decreasing. Latest-filed diluted EPS remains usable for Business Trend, but an integer share-count change lacks enough evidence to confirm a comparable EPS basis; valuation growth therefore stays at 0%.
43
Median gross margin 40.8% over 3y, variable.
0
Median ROIC -323.3%, above the 12% hurdle in 0% of years.
28
Net debt/EBITDA n/ax, interest coverage -175x.
44
Owner earnings changed trend unclear over up to the ten most recent annual observations, share count n/a.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
Above value if growth stopped todayBelow value if growth stopped today
No price data
Not reported
Unavailable — insufficient owner-earnings data
Unavailable — insufficient growth-model data
$1.75
No price data
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
7 years of fundamentals
The business, in plain English
Intelligent Bio Solutions Inc. booked $3.1M of revenue in FY2025 in the Healthcare sector and kept 40.8% of it as gross profit — a solid-margin business by that measure. After every other cost, −346.2% of each revenue dollar reached the bottom line.
Across the filed record, revenue grew from $188744 (FY2020) to $3.1M (FY2025) — about 74.5% a year compounded over 5 years.
It earned −425.5% on invested capital in the latest filed year, FY2025. Across the full 4-year measurable filed record, median ROIC was −323.3%. Over the v3 recent window (4 measurable filed years), median ROIC was −323.3%. The Returns on Capital filter above scores it 0/100.
INBS's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.
Put together: Business Trend is the strongest of the five filters (57/100) and Returns on Capital the weakest (0/100), which is how INBS lands at 34/100 — a None moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
FY2019–FY2025 · 7 fiscal years, normalized from INBS’s SEC filings
Sales, as filed$3.1M FY2025Revenue kept after cost of goods40.8% FY2025Standard ROIC or separately labeled Operating ROICROIC −425.5% FY2025Cash an owner could take out−$9.8M FY2025
Gaps in a line mean that item isn’t in INBS’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Flagship explainer
How Intelligent Bio Solutions Inc. makes its money
Intelligent Bio Solutions Inc.'s filing does not supply enough comparable lines for a truthful flow chart — here's what is filed:
· event Jun 30, 2025 · retrieved Jul 26, 2026 · annual-row source set
Curated 19-manager tier
Who reported holding Intelligent Bio Solutions Inc.
Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.
0 holding0 exited0 not holding0/19 resolved19 unavailable
Named manager positions and quarter-over-quarter changes
Manager
Reported position
Quarter-over-quarter
Filing accession
Abrams Capital
Unavailable
Comparison unavailable
Filing unavailable
Akre Capital
Unavailable
Comparison unavailable
Filing unavailable
Baupost Group
Unavailable
Comparison unavailable
Filing unavailable
Berkshire Hathaway
Unavailable
Comparison unavailable
Filing unavailable
Brave Warrior Advisors
Unavailable
Comparison unavailable
Filing unavailable
Dodge & Cox
Unavailable
Comparison unavailable
Filing unavailable
First Eagle
Unavailable
Comparison unavailable
Filing unavailable
Fundsmith
Unavailable
Comparison unavailable
Filing unavailable
Gardner Russo & Quinn
Unavailable
Comparison unavailable
Filing unavailable
Gates Foundation Trust
Unavailable
Comparison unavailable
Filing unavailable
Mairs & Power
Unavailable
Comparison unavailable
Filing unavailable
Markel / Markel-Gayner
Unavailable
Comparison unavailable
Filing unavailable
Oakmark / Harris Associates
Unavailable
Comparison unavailable
Filing unavailable
Pershing Square
Unavailable
Comparison unavailable
Filing unavailable
Polen Capital
Unavailable
Comparison unavailable
Filing unavailable
Sequoia / Ruane Cunniff
Unavailable
Comparison unavailable
Filing unavailable
Southeastern Asset Management
Unavailable
Comparison unavailable
Filing unavailable
Tweedy, Browne
Unavailable
Comparison unavailable
Filing unavailable
Yacktman Asset Management
Unavailable
Comparison unavailable
Filing unavailable
Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.
What Intelligent Bio Solutions Inc. insiders reported
Records still being gathered — partial as of retrieval Aug 18, 2026.
Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.
Moat Score history
15 logged readings since Jul 17, 2026 · append-only, never rewritten
Moat Score over timeLast scored reading of each day, on the 0–100 scale34.2 / 100
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.
Records still being gathered — partial as of retrieval Aug 18, 2026.
Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.
No reported Form 4 rows were captured for INBS; the incomplete walk cannot establish zero activity, zero counts, or a negative cluster result.
A filing source-event date will appear when a Form 4 row is captured.
Retrieved .
Track record
How Intelligent Bio Solutions Inc.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
Point-in-time scores 2021–2025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight
Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year
How to read this: each dot is what the engine would have scored INBS on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the reconstructed history shown, INBS did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.
Healthcare context
#470 of 710 scored Healthcare companies, ranked by Moat Score.
Does Intelligent Bio Solutions Inc. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores Intelligent Bio Solutions Inc. (INBS) 34.2 out of 100 — below the Shallow-moat bar, so no moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 57, pricing power 43, returns on capital 0, balance-sheet safety 28, capital allocation 44.
How has INBS's Moat Score changed over time?
The record logs 15 readings since Jul 17, 2026; the latest reads 34.2 out of 100 (no moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.
Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell INBS. See the disclaimer.